• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷酸二酯酶4抑制剂SB 207499和AWD 12 - 281对过敏性皮炎模型炎症反应的影响

Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis.

作者信息

Bäumer Wolfgang, Gorr Gilbert, Hoppmann Joachim, Ehinger Andreas M, Ehinger Britt, Kietzmann Manfred

机构信息

Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Buenteweg 17, 30559, Hanover, Germany.

出版信息

Eur J Pharmacol. 2002 Jun 20;446(1-3):195-200. doi: 10.1016/s0014-2999(02)01810-1.

DOI:10.1016/s0014-2999(02)01810-1
PMID:12098602
Abstract

The inhibitors of the phosphodiesterase 4, SB 207499 (cilomilast, c-4-cyano-4-(3-cyclopentyloxy-4-methoxy-phenyl)-r-L-cyclohexane carboxylic acid) and AWD 12-281 (N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide) were tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate. The allergic reaction was challenged by topical administration of toluene-2,4-diisocyanate onto the mice ears. Before challenge, two groups of mice were treated topically (ear skin) with SB 207499 or AWD 12-281. There was a significant ear swelling in toluene-2,4-diisocyanate-challenged mice ears 4, 8, 16, 24 and 48 h after challenge. SB 207499 and AWD 12-281 inhibited this swelling significantly 8, 16, 24 and 48 h after the challenge. For biochemical parameters and histology, ears were sampled from mice sacrificed 4, 8 and 16 h after the challenge. In homogenized tissue, SB 207499 and AWD 12-281 inhibited significantly the secretion of interleukin 1beta induced by toluene-2,4-diisocyanate 4 and 8 h after challenge. The cell influx (granulocytes) observed in the toluene-2,4-diisocyanate-challenged mice 8 and 16 h after challenge was nearly abolished by AWD 12-281 and SB 204799.

摘要

磷酸二酯酶4抑制剂SB 207499(西洛司特,c-4-氰基-4-(3-环戊氧基-4-甲氧基苯基)-r-L-环己烷羧酸)和AWD 12-281(N-(3,5-二氯吡啶-4-基)-[1-(4-氟苄基)-5-羟基吲哚-3-基]-乙醛酸酰胺)在小鼠过敏性皮炎模型中进行了测试。为诱导过敏性皮炎,将BALB/c小鼠用甲苯-2,4-二异氰酸酯致敏。通过将甲苯-2,4-二异氰酸酯局部涂抹于小鼠耳部来激发过敏反应。在激发前,两组小鼠分别用SB 207499或AWD 12-281进行局部(耳部皮肤)治疗。在激发后4、8、16、24和48小时,甲苯-2,4-二异氰酸酯激发的小鼠耳部出现明显的耳部肿胀。SB 207499和AWD 12-281在激发后8、16、24和48小时显著抑制了这种肿胀。为检测生化参数和组织学情况,在激发后4、8和16小时处死小鼠并采集耳部样本。在匀浆组织中,SB 207499和AWD 12-281在激发后4和8小时显著抑制了甲苯-2,4-二异氰酸酯诱导的白细胞介素1β分泌。在激发后8和16小时,AWD 12-281和SB 204799几乎消除了在甲苯-2,4-二异氰酸酯激发的小鼠中观察到的细胞内流(粒细胞)。

相似文献

1
Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis.磷酸二酯酶4抑制剂SB 207499和AWD 12 - 281对过敏性皮炎模型炎症反应的影响
Eur J Pharmacol. 2002 Jun 20;446(1-3):195-200. doi: 10.1016/s0014-2999(02)01810-1.
2
AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.AWD 12 - 281,一种高度选择性的磷酸二酯酶4抑制剂,在过敏性皮炎模型中对炎症反应的预防和治疗有效。
J Pharm Pharmacol. 2003 Aug;55(8):1107-14. doi: 10.1211/0022357021585.
3
Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.选择性磷酸二酯酶4抑制剂N-(3,5-二氯吡啶-4-基)-[1-(4-氟苄基)-5-羟基吲哚-3-基]-乙醛酸酰胺(AWD 12-281)在人细胞制剂中的抗炎潜力。
J Pharmacol Exp Ther. 2004 Feb;308(2):555-63. doi: 10.1124/jpet.103.059097. Epub 2003 Nov 10.
4
In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.N-(3,5-二氯吡啶-4-基)-[1-(4-氟苄基)-5-羟基吲哚-3-基]-乙醛酸酰胺(AWD 12-281)是一种用于吸入给药的选择性磷酸二酯酶4抑制剂,在气道疾病模型中的体内疗效。
J Pharmacol Exp Ther. 2003 Oct;307(1):373-85. doi: 10.1124/jpet.103.053942. Epub 2003 Aug 27.
5
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.SB 207499(阿瑞吡坦),一种第二代磷酸二酯酶4抑制剂,可在体内降低肿瘤坏死因子α和白细胞介素-4的产生。
J Pharmacol Exp Ther. 1998 Nov;287(2):705-11.
6
Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.磷酸二酯酶IV抑制剂抑制人嗜酸性粒细胞脱颗粒对额外腺苷酸环化酶激活的需求。
Eur J Pharmacol. 2001 Apr 6;417(1-2):11-8. doi: 10.1016/s0014-2999(01)00821-4.
7
Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models.新型磷酸二酯酶7A和-4双重抑制剂YM-393059对急慢性炎症模型的药理特性
Eur J Pharmacol. 2006 Nov 21;550(1-3):166-72. doi: 10.1016/j.ejphar.2006.08.023. Epub 2006 Aug 30.
8
The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice.磷酸二酯酶4抑制剂AWD 12 - 281在一种可预测人体皮肤渗透情况的过敏性皮肤炎症新豚鼠模型中具有活性,并能抑制小鼠体内的Th1和Th2细胞因子。
J Pharm Pharmacol. 2005 Dec;57(12):1609-17. doi: 10.1211/jpp.57.12.0011.
9
Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.新型磷酸二酯酶4抑制剂4-(8-苯并[1,2,5]恶二唑-5-基-[1,7]萘啶-6-基)-苯甲酸(NVP-ABE171)的药理学特性,一种具有抗炎活性的1,7-萘啶衍生物。
J Pharmacol Exp Ther. 2002 Apr;301(1):241-8. doi: 10.1124/jpet.301.1.241.
10
Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.用于治疗过敏性皮肤病和银屑病的高选择性磷酸二酯酶4抑制剂。
Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. doi: 10.2174/187152807780077318.

引用本文的文献

1
Beyond Avoidance: Advanced Therapies for Contact Dermatitis.超越回避:接触性皮炎的先进疗法。
J Allergy Clin Immunol Pract. 2024 Sep;12(9):2260-2267. doi: 10.1016/j.jaip.2024.05.035. Epub 2024 May 29.